Literature DB >> 26415576

Contemporary Animal Models For Human Gene Therapy Applications.

Chitra Gopinath, Trupti Job Nathar, Arkasubhra Ghosh, Dennis Durand Hickstein, Everette Jacob Remington Nelson1.   

Abstract

Over the past three decades, gene therapy has been making considerable progress as an alternative strategy in the treatment of many diseases. Since 2009, several studies have been reported in humans on the successful treatment of various diseases. Animal models mimicking human disease conditions are very essential at the preclinical stage before embarking on a clinical trial. In gene therapy, for instance, they are useful in the assessment of variables related to the use of viral vectors such as safety, efficacy, dosage and localization of transgene expression. However, choosing a suitable disease-specific model is of paramount importance for successful clinical translation. This review focuses on the animal models that are most commonly used in gene therapy studies, such as murine, canine, non-human primates, rabbits, porcine, and a more recently developed humanized mice. Though small and large animals both have their own pros and cons as disease-specific models, the choice is made largely based on the type and length of study performed. While small animals with a shorter life span could be well-suited for degenerative/aging studies, large animals with longer life span could suit longitudinal studies and also help with dosage adjustments to maximize therapeutic benefit. Recently, humanized mice or mouse-human chimaeras have gained interest in the study of human tissues or cells, thereby providing a more reliable understanding of therapeutic interventions. Thus, animal models are of great importance with regard to testing new vector technologies in vivo for assessing safety and efficacy prior to a gene therapy clinical trial.

Entities:  

Mesh:

Year:  2015        PMID: 26415576      PMCID: PMC7709571          DOI: 10.2174/1566523215666150929110424

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  131 in total

1.  A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration.

Authors:  Zhijian Wu; Suja Hiriyanna; Haohua Qian; Suddhasil Mookherjee; Maria M Campos; Chun Gao; Robert Fariss; Paul A Sieving; Tiansen Li; Peter Colosi; Anand Swaroop
Journal:  Hum Mol Genet       Date:  2015-04-15       Impact factor: 6.150

2.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.

Authors:  P L Felgner; T R Gadek; M Holm; R Roman; H W Chan; M Wenz; J P Northrop; G M Ringold; M Danielsen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction.

Authors:  Ajay Perumbeti; Tomoyasu Higashimoto; Fabrizia Urbinati; Robert Franco; Herbert J Meiselman; David Witte; Punam Malik
Journal:  Blood       Date:  2009-05-27       Impact factor: 22.113

4.  Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems.

Authors:  Wei Li; Fei Teng; Tianda Li; Qi Zhou
Journal:  Nat Biotechnol       Date:  2013-08       Impact factor: 54.908

Review 5.  Genome engineering with zinc-finger nucleases.

Authors:  Dana Carroll
Journal:  Genetics       Date:  2011-08       Impact factor: 4.562

6.  Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.

Authors:  Thomas R Bauer; Laura M Tuschong; Katherine R Calvo; Heather R Shive; Tanya H Burkholder; Eleanor K Karlsson; Robert R West; David W Russell; Dennis D Hickstein
Journal:  Mol Ther       Date:  2013-03-26       Impact factor: 11.454

7.  Safety and efficacy of gene transfer for Leber's congenital amaurosis.

Authors:  Albert M Maguire; Francesca Simonelli; Eric A Pierce; Edward N Pugh; Federico Mingozzi; Jeannette Bennicelli; Sandro Banfi; Kathleen A Marshall; Francesco Testa; Enrico M Surace; Settimio Rossi; Arkady Lyubarsky; Valder R Arruda; Barbara Konkle; Edwin Stone; Junwei Sun; Jonathan Jacobs; Lou Dell'Osso; Richard Hertle; Jian-xing Ma; T Michael Redmond; Xiaosong Zhu; Bernd Hauck; Olga Zelenaia; Kenneth S Shindler; Maureen G Maguire; J Fraser Wright; Nicholas J Volpe; Jennifer Wellman McDonnell; Alberto Auricchio; Katherine A High; Jean Bennett
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

8.  Graft permeabilization facilitates gene therapy of transplant arteriosclerosis in a rabbit model.

Authors:  M D Rekhter; N Shah; R D Simari; C Work; J S Kim; G J Nabel; E G Nabel; D Gordon
Journal:  Circulation       Date:  1998-09-29       Impact factor: 29.690

9.  Cardiac involvement in patients with spinal muscular atrophies.

Authors:  Alberto Palladino; Luigia Passamano; Antonella Taglia; Paola D'Ambrosio; Marianna Scutifero; Maria Rosaria Cecio; Esther Picillo; Emanuela Viggiano; Vito Torre; Francesco De Luca; Giovanni Nigro; Luisa Politano
Journal:  Acta Myol       Date:  2011-12

10.  Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update.

Authors:  B Mohty; M Mohty
Journal:  Blood Cancer J       Date:  2011-04-29       Impact factor: 11.037

View more
  3 in total

Review 1.  Treating Rett syndrome: from mouse models to human therapies.

Authors:  Neeti Vashi; Monica J Justice
Journal:  Mamm Genome       Date:  2019-02-28       Impact factor: 2.957

Review 2.  The Impact of Hyaluronic Acid on Tendon Physiology and Its Clinical Application in Tendinopathies.

Authors:  Francesco Oliva; Emanuela Marsilio; Giovanni Asparago; Antonio Frizziero; Anna Concetta Berardi; Nicola Maffulli
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

3.  Sertoli, Leydig, and Spermatogonial Cells' Specific Gene and Protein Expressions as Dog Testes Evolve from Immature into Mature States.

Authors:  Vanmathy R Kasimanickam; Ramanathan K Kasimanickam
Journal:  Animals (Basel)       Date:  2022-01-22       Impact factor: 2.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.